Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

CMI2T IA

Financiado

Cerrado

Harmless Clostridium bacteria as a highly targeted continuous delivery system f...

Harmless Clostridium bacteria as a highly targeted continuous delivery system for immunomodulatory anti cancer drugs DualTPharma (DTP) is a new venture developing a highly-potent and proprietary line of targeted pharmaceuticals for personalised cancer treatment. Our mission is to broaden our current pipeline by developing a new class of dual dru... ver más

31/08/2018

Exomnis Biotech

116K€

Presupuesto del proyecto: 116K€

Líder del proyecto

EXOMNIS BIOTECH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-08-31

INNOSUP-02-2016: European SME innovation Associate -... Specific Challenge:The lack of access to skills, to latest knowledge and capacity to manage innovati...

I+D

Cerrada hace 8 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

Exomnis Biotech

115.63K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 18 meses Fecha Inicio: 2017-02-28
Fecha Fin: 2018-08-31

Líder del proyecto

EXOMNIS BIOTECH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 116K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto DualTPharma (DTP) is a new venture developing a highly-potent and proprietary line of targeted pharmaceuticals for personalised cancer treatment. Our mission is to broaden our current pipeline by developing a new class of dual drugs for cancer treatment which are well tolerated and can be taken orally. This novel solution comprises the application of non-pathogenic Clostridium bacteria as a novel tumour delivery vehicle for anti-cancer drugs to increase immunotherapy efficacy. Even though DTP has a multi-disciplinary team available in the oncology field, we lack the required expertise and skills in the bacterial genetic field to test the feasibility and lead the development of this new line of R&D. Therefore, the goal of this project, CMI2T IA, is to hire an Innovation Associate with expertise in the bacterial genetic field for our company, to determine the feasibility of this novel solution. The successful candidate is preferably a microbiologist with an interest in bacterial applications in cancer treatment and with strong expertise in bacterial genetics. During the first 12 months, the innovation associate will be involved with both technical and business-related activities. (S)he will be responsible for establishing the new line of R&D, with activities ranging from establishing and managing a new lab to, planning research, to performing hands-on laboratory work. More specifically, the research activities will include genetic modification of bacteria, and performing in vitro efficacy assays on human cell lines. From a business perspective, the Innovation Associate will critically contribute to a market study and the development of a business strategy of the new business unit. This position will open up new career opportunities for the Innovation Associate, by obtaining transferable skills in both the business and technical field, and will leverage DTP’s growth by expanding DTP’s drug pipeline with a very novel and promising cancer drug delivery candidate.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores